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A B S T R A C T
We aim to describe survival outcomes of gynecologic oncology inpatients treated with intravenous bisphosphonates for hypercalcemia and develop a risk stratiﬁ-
cation model that predicts decreased survival to aid with goals of care discussion. In a single-center, retrospective cohort study of gynecologic oncology patients
admitted for bisphosphonate therapy for hypercalcemia. Survival from hypercalcemia to death was assessed by Kaplan-Meier method and log-rank test. Univariate
log-rank test and Cox proportional hazards modeling were used to develop a risk stratiﬁcation model. Sixty-ﬁve patients were evaluable with a median follow-up of
83.5 months. Mean age was 59.2 years, 64.6% had recurrent disease, and 30.8% had≥2 previous lines of chemotherapy. Median survival was 38 days. Our analysis
identiﬁed four risk factors (RFs) [brain metastasis, > 1 site of metastasis, serum corrected peak calcium>12.4 (mg/dL), and peak ionized calcium>5.97 (mg/dL)]
that predicted survival and were used to build a risk stratiﬁcation score. Sum of RFs included 35 patients with 1 RF, 11 had 2 RFs, and 19 had≥3 RF. Median survival
for 1, 2, or≥ 3 RFs was 53, 28, and 26 days respectively (p= .009). Survival at 6 months was 28.6%, 18.2%, and 5.3% for each group respectively. Hospice
enrollment was 26.2%, and did not vary by group (p= .51). Among gynecologic oncology patients, inpatient management of hypercalcemia with bisphosphonates
portends poor prognosis. Individualized risk stratiﬁcation may help guide end-of-life discussions and identify patients who may beneﬁt most from hospice care.
1. Introduction
Hypercalcemia associated with cancer aﬀects up to 30% of oncology
patients and portends high morbidity and poor mortality (Stewart,
2005). It may lead to central nervous system disturbances, renal failure,
constipation, nausea, and pain (Ralston et al., 1990). These associated
ﬁndings have been previously studied among cancer patients and re-
ported to occur with a median of 30–55 days prior to death (Ralston
et al., 1990; Ling et al., 1995). Hypercalcemia associated with solid
tumors is most frequently due to humoral responses caused by para-
thyroid hormone related protein (PTHrP) secreted by the tumor
(Nakayama et al., 1996). PTHrP causes hypercalcemia via enhancing
renal retention of calcium and increases bone resorption (Horwitz et al.,
2003). First line treatment for hypercalcemia associated with cancer is
intravenous (IV) bisphosphonates such as pamidronic or zoledronic
acid. These medications will combat the tumor's eﬀects by inhibiting
osteoclast bone resorption (Major et al., 2001).
Use of bisphosphonates may eﬀectively decrease a patient's elevated
calcium or symptoms. Bisphosphonates may improve breast cancer
survival but this ﬁnding has not been adequately studied in gynecologic
malignancies (Wright et al., 2015; Early Breast Cancer Trialists'
Collaborative, G, 2015). Generally, the diagnosis of hypercalcemia is
poor prognostic feature that may aid in discussions of goals of care.
There is a paucity of data looking at the utilization of specialty pallia-
tive care consultation or hospice initiation when patients are found to
experience hypercalcemia.
Outcomes of hypercalcemia in women with a gynecologic malig-
nancy has not been well studied and at best, limited to small numbers
embedded in published reports that captures oncology patients re-
gardless of primary site (Stewart, 2005; Ralston et al., 1990; Stewart
et al., 1982). Our objective was to describe clinical and demographic
characteristics of women with a gynecologic malignancy, admitted to
an inpatient academic medical center with symptomatic hypercalcemia.
Secondary objectives were to determine the prognostic value of hy-
percalcemia to predict OS and identify subgroups that would beneﬁt
most from hospice care.
2. Methods
After receiving approval by the Washington University Human
Research Protection oﬃce (#201712061), we performed a single-
center, retrospective cohort study of women with a gynecologic
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malignancy admitted for inpatient management of hypercalcemia be-
tween 9/1/2012-10/1/2017. Our cohort was identiﬁed by querying the
inpatient pharmacy records of intravenous (IV) pamidronic or zole-
dronic acid administration. Patients were included if they met the fol-
lowing criteria: 1) admitted to the gynecologic oncology service with a
conﬁrmed gynecologic malignancy of any stage or type, 2) had a serum
calcium or serum albumin-corrected calcium level of 10.2mg/dL or
higher, and 3) received IV pamidronic or zoledronic acid. The calcu-
lation of albumin-corrected calcium=Serum calcium +0.8 ∗ (4 g/dL-
patient's albumin g/dL). All patients were considered to have sympto-
matic hypercalcemia but severity of symptoms was not quantiﬁed. No
patients were readmitted and no patient was accounted in our analysis
more than once.
Survival was assessed by Kaplan-Meier method and log-rank test. OS
was calculated from date of hypercalcemia to date of expiration. We
performed univariate analysis with the log-rank test to identify clinical
and demographic factors that predicted decreased survival. Those risk
factors found to be statistically signiﬁcant (eg, presence of brain me-
tastasis and > 1 site of metastasis; p < .05) were then adjusted for in
our Cox proportional hazard regression model to identify a predictive
serum markers (eg, albumin-corrected peak calcium, peak ionized cal-
cium, and albumin) to be used in our risk stratiﬁcation model. Median
lab values of> 5.9mg/dL for ionized calcium and> 12.4mg/dL for
serum corrected calcium were used as cutoﬀs to ensure adequate
sample size for analysis. Lastly both ionized calcium and serum cor-
rected calcium were included as 20 patients did not have an ionized
calcium measured during their hospitalization.
Four signiﬁcant factors from both univariate and multivariate ana-
lyses (presence of brain metastasis, > 1 site of metastasis, ionized cal-
cium>5.9mg/dL, and serum corrected calcium>12.4 mg/dL), were
used to build a prognostic risk stratiﬁcation system. Scores were de-
termined by the sum of predictive variables with a possible maximum
score of 4. Median survivals of patients with score 0, 1, 2, and≥3 were
determined with Kaplan-Meier method and compared using log-rank
test. P-values ≤.05 were considered statistically signiﬁcant. All statis-
tical analyses were performed using SAS version 9.4 (SAS Institute,
Cary, NC).
3. Results
We identiﬁed 1260 patients who received IV pamidronic or zole-
dronic acid during the study period. Gynecologic malignancy occurred
in 116 patients, and 51 were excluded secondary to normal calcium
levels. Therefore, 65 patients were included in this analysis and of
these, 55 were deceased at last follow-up, and 10 were long-term sur-
vivors with median follow-up of 83.5 months from diagnosis of hy-
percalcemia.
The mean age was 59.2 years old, most were white (73.9%) and
privately insured (41.5%). Disease site origin was heterogenous with
35.4% uterine, 29.2% ovarian, and 24.6% cervical. The most frequent
histologies were squamous (29.2%), adenocarcinoma (21.5%), and
serous (16.9%). The majority of patients at time of inpatient admission
had 2 or more sites of metastatic disease (89%), the most common lo-
cations included abdomen (89.2%), bone (49.2%), lung (36.9%), liver
(33.9%), and brain (6.2%). More than half suﬀered from recurrent
disease (64.6%) and 30.8% had 2 or more previous lines of che-
motherapy (Table 1).
Details of hospital admission are summarized in Table 2. Most pa-
tients were admitted for< 7 days (55.4%). Admission diagnoses be-
yond hypercalcemia included pain (46.2%), inanition “failure to thrive”
(20.0%), nausea (18.5%), and underlying infectious process (13.9%).
The severity of hypercalcemia also varied; median serum corrected
peak calcium levels 12.4mg/dL (range, 10.2–18.5), and median serum
peak ionized calcium levels 5.97mg/dL (range, 3.5–8.9). The majority
of patients demonstrated signs of protein calorie malnutrition with
75.4% having a serum albumin< 3.5 g/dL. During admission, 73.9%
received specialty palliative care consultation, and 26.2% were dis-
charged with hospice services.
Median OS for the entire cohort was 38 days (Fig. 1). Univariate
analysis revealed that presence of brain metastasis (compared to no
brain metastasis) and > 1 metastatic site (versus 1 metastatic site)
were associated with a statistically signiﬁcant decrease in OS (Table 3).
After adjusting for both of these variables in our Cox regression model,
serum corrected peak calcium>12.4 (mg/dL), and peak ionized cal-
cium>5.97 (mg/dL) were associated with worse median survival (aHR
1.88, 95% CI 1.1–3.3; and aHR 2.43, 95% CI 1.26–4.68 respectively).
Next we identiﬁed subgroups based upon a risk factor (RF) strati-
ﬁcation system to predict OS. Stratiﬁed by number of RFs present (1, 2
or ≥3 among brain metastasis, > 1 site of metastasis, serum ionized
calcium>5.9mg/dL, and serum corrected calcium>12.4 mg/dL), 35
patients had 1 RF, 11 had 2 RFs, and 19 had≥3 RF. Median survival for
Table 1
Clinicodemographic features.
Mean
Age 59.2 years
BMI 27.5 kg/m2
N %
Race
White 48 73.9%
African American 14 21.5%
Asian 1 1.5%
Hispanic 1 1.5%
Other 1 1.5%
Insurance
Private 27 41.5%
Medicaid 9 13.9%
Medicare 27 41.5%
Self-pay 2 3.1%
Disease site
Ovary 19 29.2%
Uterus 23 35.4%
Cervix 16 24.6%
Other 7 10.7%
Histology
Adenocarcinoma 14 21.5%
Squamous 19 29.2%
Serous 11 16.9%
Clear cell 5 7.7%
Carcinosarcoma 5 7.7%
Neuroendocrine 4 6.2%
Other 7 10.8%
Initial stage
I 5 7.7%
II 6 9.2%
III 25 38.5%
IV 29 44.6%
Cancer setting
Primary 23 35.4%
Recurrent 42 64.6%
Previous lines of chemotherapy
0 26 40.0%
1 19 39.2%
2 10 15.4%
≥3 10 15.4%
Sum of metastatic sites
1 7 10.8%
2 18 27.7%
3 24 36.9%
≥4 16 24.6%
Location of metastasis
Abdomen 58 89.2%
Bone 32 49.2%
Lung 24 36.9%
Liver 22 33.9%
Brain 4 6.2%
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1, 2, or ≥3 RFs was 53, 28, and 26 days respectively (Fig. 2, log-rank
p= .009). Survival at 6months was 28.6%, 18.2%, and 5.3% for each
risk group respectively. Despite a signiﬁcant increase in specialty
palliative care services from 60% in those with 1 RF to 94.7% with
≥3RF (p= .017), there was no diﬀerence in hospice enrollment by RF
(p= .51). Of the 17 hospice enrollees, 8 had 1RF, 2 had 2RF, and 7 had
≥3RF.
Adjuvant chemotherapy was delivered to 18 patients and 7 (38.9%)
were treated within the last 30 days of life. However there were 6 pa-
tients with durable responses (304–1994 days), all of whom had only 1
RF.
4. Discussion
Our ﬁndings suggest hypercalcemia associated with gynecologic
cancers portends a poor prognosis and when additional RFs are present
(eg, brain metastasis, > 1 site of metastasis, ionized calcium≥5.9mg/
dL, and serum corrected calcium ≥12.4mg/dL) should prompt dis-
cussions regarding goals of care with consideration of focusing on
palliation of symptoms and hospice enrollment. Our cohort's median
survival was only 38 days which is considerably less than that reported
by Penel et al. (Ralston et al., 1990; Penel et al., 2008) and Ralston et al.
(Ralston et al., 1990; Penel et al., 2008) of 64 and 126 days, respec-
tively. The most striking diﬀerence which can account for such dis-
crepancy is our inpatient admission criteria as compared to the prior
studies which focused on the outpatient setting.
Adding to the literature on hypercalcemia, we were able to de-
monstrate a risk stratiﬁcation system among gynecologic oncology in-
patients that correlates increasing number of RFs (eg, brain metas-
tasis), > 1 site of metastasis, serum corrected peak calcium>12.4mg/
dL, and peak ionized calcium>5.97mg/dL with worse OS. This is
consistent with a prior study by Penel et al. (Penel et al., 2008; Penel
et al., 2009) that included 260 oncology patients, of which 10.7% had a
conﬁrmed gynecologic malignancy. They showed a similar survival
trend based on a three-tier risk stratiﬁcation system based on four in-
dependent predicting factors: serum-corrected calcium>2.83mol/L,
albuminemia<35 g/L, squamous cell cancer type, and presence of
liver or bone metastases (Penel et al., 2008). Unlike other studies
however, we did not detect a signiﬁcant diﬀerence in women with
primary versus recurrent disease status (58 and 33 days, p= .2) Nor did
we ﬁnd a signiﬁcant association between OS and presence of visceral
mets as demonstrated in other non-gynecologic cancers (de Wit &
Table 2
Admission details.
N %
Hospital duration
<7 days 36 55.4%
≥7 days 29 44.6%
Admission diagnosis
Pain 30 46.2%
Inanition (“Failure to thrive”) 13 20.0%
Nausea 12 18.5%
Infection 9 13.9%
Renal failure 7 10.8%
Anemia 7 10.8%
VTE/PE 6 9.2%
Bowel obstruction 2 3.1%
Other 9 13.9%
Peak serum corrected calcium
> 12.4 31 47.7%
≤ 12.4 34 52.3%
Peak ionized calciuma
>5.97 21 32.3%
≤5.97 24 36.9%
Admission albumin
>3.5 16 24.6%
≤3.5 49 75.4%
In hospital death
Yes 19 29.2%
No 46 70.8%
Specialty palliative care consult
Yes 48 73.85%
No 17 26.15%
Discharge location
Home 40 61.5%
Hospice 17 26.2%
SNF 8 12.3%
Readmission within 30 days
Yes 27 41.5%
No 38 58.5%
a N of 45.
Fig. 1. Overall survival. Median survival for entire cohort was 38 days (95%CI: 28–56, range: 2–1994).
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Cleton, 1994; Truong et al., 2003).
The presence of multiple RFs correlated with specialty palliative
care consultation, but not hospice enrollment. The prognostic value of
our proposed risk stratiﬁcation system to predict mortality among gy-
necologic oncology patients highlights the potential for a practical and
objective tool to aid providers in the discussion of goals of care and if
appropriate, initiation of hospice. Considering Medicare eligibility cri-
teria for hospice includes documentation of a terminal illness with a
prognosis of six months or less, the four independent factors used in our
risk stratiﬁcation contribute distinct survival curves with relevant time
intervals based on the number of RFs present. These ﬁndings should be
replicated in a larger dataset before integrating the presence of hy-
percalcemia into clinical decision making at the end of life, but if
conﬁrmed may aid in avoiding futile treatments and allow for emphasis
on management strategies that optimize quality of life.
Strengths of our study revolve around our unique study population
and volume. Given our wide referral base as academic institution with
an aﬃliated cancer center, our study represents one of the largest
publications to date regarding hypercalcemia in gynecologic
malignancies. Although only 65 women were studied, we were able to
stratify prognosis based on the risk factors. Previous data frequently
include a heterogenous group of oncology patients with minimal to no
gynecologic representation. Nonetheless, we acknowledge limitations
posed by the infrequent incidence of hypercalcemia in gynecologic
oncology patients. Limitation include underpowered analysis to com-
pare survival outcomes between staged-matched patients with and
without hypercalcemia. Additionally, we were unable to control for
performance status, serum level of PTHrP, or other confounding co-
morbidities. Our data does shed light on the prognostic value of in-
patient management of hypercalcemia and consideration to initiate
conversations regarding hospice care in the highest risk patients. We
acknowledge that our results may not apply to patients in the out-
patient setting.
In conclusion, our data aﬃrm the poor prognostic value of inpatient
management of hypercalcemia associated with gynecologic malig-
nancies. Individualized risk stratiﬁcation based on four clinical
RFs—brain metastasis, > 1 site of metastasis, serum corrected peak
calcium>12.4mg/dL, and peak ionized calcium>5.97 (mg/dL),
suggest that patients of high risk may beneﬁt from end-of-life decision
making and appropriately identify patients who may beneﬁt from
hospice care.
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Table 3
Univariate analysis.
Median survival
(days)
95% CI
(days)
p value (log-
rank)
Age
<65 49 (29, 62) 0.23
≥65 28 (13, 45)
BMI
< 30 37 (26, 58) 0.57
30–39.9 42 (9, 211)
≥ 40 30 (28, 161)
Race
White 41 (28, 62) 0.43
African American 29 (15, 53)
Other 38 (21, 66)
Disease site
Ovary 30 (13, 66) 0.84
Uterus 49 (28, 78)
Cervix 30 (21, 68)
Other 37 (2,53)
Histology
Adenocarcinoma 31 (11, 161) 0.68
Squamous 38 (24, 56)
Other 47 (28, 66)
Cancer Setting
Primary 58 (25, 119) 0.20
Recurrent 33 (27, 45)
Previous lines of chemo
0 43 (25, 65) 0.77
1 42 (21, 161)
2 33 (9, 53)
≥ 3 39 (6, 66)
Sum of metastatic sites
1 304 NA 0.01
2 64 (28, 68)
3 39 (17, 56)
≥ 4 25 (11, 45)
Bone metastasis
Presence 42 (21, 62) 0.47
Absence 37 (28, 62)
Lung metastasis
Presence 30 (14, 53) 0.15
Absence 42 (28, 66)
Brain metastasis
Presence 22 (15, 27) 0.01
Absence 42 (29, 58)
Liver metastasis
Presence 30 (17, 62) 0.15
Absence 42 (28, 62)
Abdomen metastasis
Presence 35 (27, 53) 0.23
Absence 65 (11, NA)
NA: not able to calculate 95% CI.
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Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.gore.2019.01.005.
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